M&T Bank Corp increased its position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) by 62.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 130,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 50,000 shares during the quarter. M&T Bank Corp owned approximately 0.08% of Antares Pharma worth $419,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. MML Investors Services LLC increased its position in shares of Antares Pharma by 228.2% during the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 30,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Antares Pharma by 10.1% during the second quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock worth $19,920,000 after purchasing an additional 567,144 shares in the last quarter. Northern Trust Corp increased its position in shares of Antares Pharma by 478.1% during the second quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after purchasing an additional 1,368,131 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $651,000. Finally, Menta Capital LLC purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $297,000. Hedge funds and other institutional investors own 36.77% of the company’s stock.

In related news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.60% of the company’s stock.

Shares of Antares Pharma, Inc. (NASDAQ:ATRS) opened at 3.89 on Monday. Antares Pharma, Inc. has a one year low of $1.41 and a one year high of $3.97. The firm has a 50-day moving average price of $3.14 and a 200 day moving average price of $2.97. The stock’s market capitalization is $608.42 million.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million during the quarter, compared to analysts’ expectations of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. On average, equities analysts expect that Antares Pharma, Inc. will post ($0.11) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “M&T Bank Corp Raises Position in Antares Pharma, Inc. (ATRS)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/10/09/mt-bank-corp-raises-position-in-antares-pharma-inc-atrs.html.

Several brokerages recently commented on ATRS. HC Wainwright set a $5.00 price target on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Vetr cut Antares Pharma from a “buy” rating to a “hold” rating and set a $3.42 price target for the company. in a research report on Wednesday, July 12th. Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Chardan Capital began coverage on Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target for the company. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $4.34.

Antares Pharma Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.